Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
The chart shows the growth of an initial investment of $10,000 in Edwards Lifesciences Corp, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Edwards Lifesciences Corp (EW) has returned -5.16% so far this year and 19.23% over the past 12 months. Looking at the last ten years, EW has achieved an annualized return of 9.05%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Edwards Lifesciences Corp (EW) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.80% | 6.18% | -6.53% | 0.06% | ||||||||
| 2025 | -2.50% | 0.13% | 0.44% | 4.59% | 3.55% | 0.93% | 2.07% | 2.94% | -3.69% | 5.99% | 3.91% | -1.56% |
| 2024 | 3.67% | 8.40% | 13.22% | -11.55% | 3.32% | 4.48% | -30.18% | 10.96% | -5.34% | 1.41% | 6.24% | 5.35% |
| 2023 | 0.91% | 1.68% | 3.31% | 6.89% | -3.76% | 12.22% | -12.34% | -6.17% | -10.24% | -7.46% | 6.63% | 13.03% |
| 2022 | -15.39% | 2.54% | 4.78% | -11.48% | -4.61% | -6.00% | 5.92% | -9.73% | -7.57% | -13.41% | 5.30% | -4.35% |
| 2021 | -9.75% | -0.53% | -0.42% | 13.74% | 0.05% | 7.12% | 8.37% | 4.23% | -3.65% | 5.74% | -10.88% | 19.50% |
| 2020 | -4.41% | -6.68% | -8.88% | 20.27% | 4.52% | -8.22% | 13.51% | 9.24% | -6.19% | -10.81% | 14.74% | 7.89% |
| 2019 | 12.18% | 1.04% | 12.01% | -8.56% | -3.20% | 8.83% | 14.04% | 4.00% | 9.23% | 2.16% | -4.98% | |
| 2018 | 13.34% | 5.68% | 4.40% | -8.53% | 6.52% | 5.36% | -1.66% | 1.11% | 20.52% | -15.54% | 8.89% | -6.64% |
| 2017 | 2.60% | -2.56% | -0.51% | 16.70% | 4.69% | 2.34% | -2.88% | -1.91% | -3.94% | -6.54% | 14.49% | -3.87% |
| 2016 | 20.67% | -7.70% | 1.21% | 14.71% | 0.54% | 4.38% | -20.64% | -13.25% | 13.16% |
The charts below present risk-adjusted performance metrics for Edwards Lifesciences Corp (EW) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of EW compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Edwards Lifesciences Corp volatility is 1.69%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 13.70B | 9.36B | 8.29B | 8.50B | 7.24B | 6.49B | 5.32B | 5.70B | 4.51B | 4.06B | 3.52B | 2.72B | 2.22B | 1.98B |
| Equity Attributable To Parent (USD) | 10.34B | 6.65B | 5.81B | 5.84B | 4.57B | 4.15B | 3.14B | 2.96B | 2.62B | 2.50B | 2.19B | 1.56B | 1.48B | 1.34B |
| Equity Attributable To Noncontrolling Interest (USD) | - | 69.40M | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 10.34B | 6.72B | 5.81B | 5.84B | 4.57B | 4.15B | 3.14B | 2.96B | 2.62B | 2.50B | 2.19B | 1.56B | 1.48B | 1.34B |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | - | - | 219.90M | - | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | - | - | 600.00M | - | - |
| Noncurrent Liabilities (USD) | 1.55B | 1.45B | 1.46B | 1.63B | 1.77B | 1.44B | 1.31B | 1.34B | 1.36B | 1.08B | 898.50M | 819.90M | 394.80M | 307.40M |
| Other Current Liabilities (USD) | 1.12B | 622.80M | 551.80M | 508.10M | 460.70M | 426.20M | 516.50M | 1.04B | 219.30M | 412.30M | 376.20M | 297.20M | 272.70M | 250.20M |
| Wages (USD) | 467.50M | 371.20M | 268.70M | 319.70M | 236.70M | 295.80M | 226.10M | 249.40M | 216.10M | - | - | - | - | - |
| Accounts Payable (USD) | 227.50M | 201.40M | 201.90M | 204.50M | 196.50M | 180.40M | 134.00M | 116.60M | 97.10M | 63.90M | 58.20M | 48.40M | 74.70M | 85.00M |
| Current Liabilities (USD) | 1.81B | 1.20B | 1.02B | 1.03B | 893.90M | 902.40M | 876.60M | 1.40B | 532.50M | 476.20M | 434.40M | 345.60M | 347.40M | 335.20M |
| Liabilities (USD) | 3.36B | 2.64B | 2.49B | 2.67B | 2.66B | 2.34B | 2.18B | 2.74B | 1.89B | 1.56B | 1.33B | 1.17B | 742.20M | 642.60M |
| Other Non-current Assets (USD) | 4.02B | 3.15B | 3.28B | 3.45B | 2.42B | 2.11B | 1.83B | 2.02B | 1.49B | 1.32B | 763.40M | 520.10M | 489.30M | 440.80M |
| Intangible Assets (USD) | 1.13B | 428.40M | 285.20M | 323.60M | 331.40M | 336.50M | 343.20M | 468.00M | 204.80M | 205.40M | 23.40M | 57.20M | 67.00M | 66.90M |
| Fixed Assets (USD) | 1.81B | 1.75B | 1.63B | 1.55B | 1.40B | 1.06B | 867.50M | 679.70M | 580.00M | 482.50M | 442.90M | 421.60M | 373.30M | 304.30M |
| Noncurrent Assets (USD) | 6.96B | 5.33B | 5.20B | 5.32B | 4.15B | 3.50B | 3.04B | 3.16B | 2.27B | 2.01B | 1.23B | 998.90M | 929.60M | 812.00M |
| Other Current Assets (USD) | 5.48B | 2.72B | 2.11B | 2.37B | 2.21B | 2.28B | 1.63B | 1.92B | 1.80B | 1.66B | 1.95B | 1.37B | 969.30M | 872.20M |
| Prepaid Expenses (USD) | 135.00M | 146.80M | 110.00M | 85.20M | 75.10M | 59.10M | 54.30M | 60.60M | 45.90M | 45.10M | 48.80M | 46.80M | 41.60M | 35.00M |
| Inventory (USD) | 1.13B | 1.17B | 875.50M | 726.70M | 802.30M | 640.90M | 607.00M | 554.90M | 396.60M | 339.90M | 296.80M | 308.90M | 281.00M | 261.30M |
| Current Assets (USD) | 6.74B | 4.04B | 3.10B | 3.18B | 3.09B | 2.98B | 2.29B | 2.53B | 2.24B | 2.05B | 2.29B | 1.73B | 1.29B | 1.17B |
| Assets (USD) | 13.70B | 9.36B | 8.29B | 8.50B | 7.24B | 6.49B | 5.32B | 5.70B | 4.51B | 4.06B | 3.52B | 2.72B | 2.22B | 1.98B |
ORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data to determine if the valuation is justified.
The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.
Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.
A U.S. District Court granted the FTC's motion to block Edwards Lifesciences' $1.2 billion acquisition of JenaValve Technology, citing concerns that the deal would eliminate competition in the TAVR-AR device market and potentially harm innovation and patient access. Despite the setback, Edwards raised its 2026 adjusted EPS guidance to $2.90-$3.05 and continues advancing its own transcatheter aortic regurgitation valve.
The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.
The transcatheter heart valve replacement market is projected to grow from $6.40 billion in 2025 to $19.98 billion by 2033, with a 15.32% CAGR, driven by rising valvular heart disease prevalence and preference for minimally invasive cardiac procedures.
The global interventional cardiology devices market is expected to grow from $20 billion in 2024 to $35 billion by 2032, driven by rising cardiovascular disease rates, technological advancements, and increasing adoption of minimally invasive procedures.
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.
